Pharmacogenomics (PGx) is the science of understanding the influence of a person’s genome on drug treatment outcomes. Provider-based PGx programs are not currently widespread—they mostly exist in large academic medical centers and in some community hospitals with strong use cases (e.g., those with large oncology or mental health patient populations).
A wide variety of health care companies are involved in the PGx process. As a result, cross-stakeholder collaboration is inherent and vital to the PGx workflow. Stakeholders include health systems (e.g., pharmacists, clinicians, IT leaders), lab vendors, clinical decision support (CDS) vendors, electronic health record (EHR) vendors, life sciences companies, and payers. Many of these groups, however, use different vocabularies to discuss PGx, creating barriers to essential cross‑industry collaboration.
As the PGx field grows, it’s important to bring these stakeholders across the health care ecosystem to a shared understanding of the topic to foster collaboration. Use the below resources to educate yourself and your organization about PGx and to also gain the buy-in you need to start or grow a health system PGx program.
Download this interactive glossary to learn about 20 terms that stakeholders most often confuse or use differently, as well as terms that are essential to understand the PGx workflow.
Download this cheat sheet to educate yourself or your teams on the what PGx is, how it works, and why it matters.
The Emerging Role of PGx
Download these ready-to-use slides to gain buy-in for your health system PGx program. You can edit based on your organization’s preferences and use the scripting points to help make your case.